Inspire Pharmaceuticals — Technical Presentation (October 2008)
28 slides from Inspire Pharmaceuticals's technical presentation, Oct 24, 2008
Slide 1: A Phase 3 Study of Denufosol for Cystic Fibrosis: TIGER-1 Results
A Phase 3 Study of Denufosol for Cystic Fibrosis: Professor of Pediatrics Cystic Fibrosis Center Director The Children’s Hospital University of Colorado Denver Exhibit 99.2 A Phase 3 Study of Denufosol for Cystic Fibrosis: TIGER-1 Results TIGER-1 Results Lead PI TIGER-1 Lead PI TIGER- 1 Frank Accurs
Slide 2: Cystic Fibrosis Therapies
2 Significant need for agent that addresses basic defect of ion transport prior to onset of infection and inflammation: Antibiotic Mucus Regulation Anti- Inflammatory Gene Therapy, Potentiator /Corrector Lung structural damage CFTR defect Thickened airway secretions Bacterial colonization Irreversib
Slide 3: TIGER-1 Clinical Study Design
3 CF patients 5 years with FEV 1 75% predicted Standard of care allowed 352 CF patients randomized at 62 treatment centers denufosol 60 mg TID (n=314) period treatment period 24-week safety extension period 1-week post-treatment follow-up placebo TID (n=174) Placebo-controlled 24-week Screening denu
Slide 4: Demographic and Background Characteristics (ITT Population)
4 89 % 95 % Pancreatic enzymes 82 % 79 % Bronchodilators 39 % 40 % Chronic macrolides 37 % 38 % Chronic inhaled antibiotics 77 % 77 % Dornase alfa 42 % 48 % PA + status 81 % 84 % FEF 25%-75% % Predicted 93 % 92 % FEV 1 % Predicted 54 % 49 % % Males 38 (21 % ) 33 (19 % ) 19 n ( % ) 59 (33 % ) 64 (37
Slide 5: Disposition by Treatment Group
5 5 (3%) 2 (1%) Discontinued from placebo-controlled phase due to an AE, n (%) 19 (11%) 18 (10%) Discontinued early: placebo-controlled phase, n (%) 159 (89%) 156 (90%) Completed through Week 24, n (%) 178 (100%) 174 (100%) Intent-to-treat population, n (%) 178 174 Randomized, n Denufosol Placebo Di
Slide 6: Primary Efficacy Results – Placebo-Controlled (ITT)
6 Met primary efficacy endpoint: change in FEV 1 from baseline to endpoint* 45 mL treatment effect (p = 0.047) “Real world” design Broader population Patients on multiple therapies that improve FEV 1 Primary Efficacy Results – Placebo – Controlled (ITT) Placebo Denufosol *Endpoint is the Week 24 val
Slide 7: Mean Change from Baseline FEV1 by Treatment Week
7 Treatment Week -40 -20 Mean Change from Baseline FEV CFB=Change from Baseline ITT Population Placebo Denufosol
Slide 8: Mean Change from Baseline FEV1 by Treatment Week
8 Treatment Week -40 -20 Mean Change from Baseline FEV CFB=Change from Baseline ITT Population Placebo Denufosol
Slide 9: Mean Change from Baseline FEV1 with Open-Label Phase
9 Treatment Week -40 -20 Mean Change from Baseline FEV CFB=Change from Baseline ITT Population Placebo Denufosol Placebo Switched to Denufosol denufosol-only, open-label phase
Slide 10: Mean Change from Baseline FEF 25%-75%
10 Treatment Week Placebo Denufosol Mean Change from Baseline FEF 25%-75% -100 -80 -60 -40 -20 CFB=Change from Baseline ITT Population
Slide 11: Mean Change from Baseline FEF 25%-75%
11 Treatment Week Placebo Denufosol Mean Change from Baseline FEF 25%-75% -100 -80 -60 -40 -20 CFB=Change from Baseline ITT Population
Slide 12: Mean Change from Baseline FEF 25%-75% with Open-Label Phase
12 Treatment Week Placebo Denufosol Placebo Switched to Denufosol Mean Change from Baseline FEF 25%-75% -100 -80 -60 -40 -20 denufosol-only, open-label phase CFB=Change from Baseline ITT Population
Slide 13: Effect of Denufosol in ITT Population and 110% Predicted Patients
13 ITT p-value = 0.047 (n=352) 110% Predicted p-value = 0.015 (n=329) ITT p-value = 0.072 (n=352) 110% Predicted p-value = 0.025 (n=329) FEV 1 FEF 25%-75% Effect of Denufosol in ITT Population and Patients 110% Predicted
Slide 14: Secondary Efficacy Endpoint: Pulmonary Exacerbation
14 Incidence as expected in this patient population (i.e. low) No significant difference between groups May be confounded by denufosol’s pharmacology Longer treatment time may be needed Secondary Efficacy Endpoint: Pulmonary Exacerbation
Slide 15: Pulmonary Exacerbations During Placebo-Controlled Phase
15 Time (Weeks) Pulmonary Exacerbations (Fuchs’ Criteria) During Placebo – Controlled Phase Placebo Denufosol 60 mg Log rank statistic = 2.379 p-value = 0.123 ITT Population
Slide 16: Hospitalizations/Missed School and Work
16 3.6 (7.7) 13 (7.3%) Denufosol (n=178) 0.610 3.4 (7.9) Mean Days of CF-Related Missed School or Work (SD) 0.843 14 (8.0%) Hospitalizations/ ER visits for respiratory complaint, n (%) P-value Placebo (n=174) Hospitalizations/Missed School and Work During Placebo–Controlled Phase ITT Population
Slide 17: Cystic Fibrosis Questionnaire – Respiratory Subscale
17 -3.08 (15.43) -1.48 (16.74) CFB Week 24 81.4 (14.56) (n=173) Mean (SD) Denufosol 79.3 (15.98) Baseline (n=162) Mean (SD) CFQ - Respiratory Placebo Cystic Fibrosis Questionnaire – Respiratory Subscale ITT Population
Slide 18: High Level of Compliance with TID Dosing
18 Compliance during the placebo-controlled phase ~90% of patients were compliant Comparable between denufosol and placebo Average number of daily doses = 2.7 Excellent patient retention throughout study 352 patients were randomized ~90% completed the 24-week placebo-controlled phase ~99% of those w
Slide 19: Most Common AEs
19 20 (11%)* 43 (25%) Headache 36 (20%) 27 (15%) Pyrexia 61 (34%) 51 (29%) Pulmonary exacerbation 15 (8%) 23 (13%) Pseudomonas infection 17 (10%)* 31 (18%) Sinusitis 29 (16%) 30 (17%) Productive cough 18 (10%)* 31 (18%) Rhinorrhea 34 (19%) 32 (18%) Pharyngolaryngeal pain 26 (15%) 34 (19%) Nasal cong
Slide 20: No Difference in Growth Between Groups
20 45.3 44.5 Baseline 0.922 1.01 1.03 CFB at 6 months 19.8 0.03 147.5 1.90 Denufosol (n=177) 0.769 19.3 0.07 BMI, kg/m Baseline CFB at 6 months Weight, kg 0.871 148.1 1.83 Height, cm Baseline CFB at 6 months P-value Placebo (n=175) Mean Change from Baseline (CFB) 2 No Difference in Growth Between Gr
Slide 21: Safety Overview
21 Safety and tolerability profile - favorable Relatively few SAEs and withdrawals due to AEs AE profile Comparable between treatment groups SAEs comparable between treatment groups Placebo: 14 (8%) Denufosol: 16 (9%) No evidence of systemic adverse effects (labs, vital signs) Minimal to no systemic
Slide 22: TIGER-1 Summary
22 Large multicenter, randomized, double-blind, placebo-controlled trial Used with other therapies No significant interactions with concomitant medications Significant improvement in FEV 1 Comparable exacerbation rates Well-tolerated Good adherence to TID regimen TIGER-1 Summary
Slide 23: Primary Efficacy Results – Placebo-Controlled (ITT)
23 Placebo Denufosol Primary Efficacy Results – Placebo – Controlled (ITT) Endpoint is the Week 24 value or the last observation carried forward for patients who withdrew early.
Slide 24: Subgroup: FEV1 in Patients Who Did Not Experience an Exacerbation
24 = 41 mL p-value = 0.101 -150 -100 -50 Subgroup: FEV in Patients Who Did NOT Experience an Exacerbation (Fuchs ’ Criteria) n=141 (81%) n=131 (74%) Placebo Denufosol
Slide 25: Subgroup: FEV1 in Patients Who Did Experience an Exacerbation
25 = 101 mL p-value = 0.062 -150 -100 -50 Subgroup: FEV in Patients Who Did Experience an Exacerbation (Fuchs ’ Criteria) n=33 (19%) n=47 (26%) Placebo Denufosol
Slide 26: Projected Long-term Impact of Slowing the Rate of Decline
26 Projected Long-term Impact of Slowing the Rate of Decline Konstan., Pediatr Pulmonol., 2008. 43, S24-28
Slide 27: TIGER-2 Study Design
27 Current Status ~100 sites in North America, Australia and New Zealand As of October 17, 133 patients randomized at 41 sites TIGER-2 Study Design Primary outcome: FEV 1 48 weeks; placebo-controlled Planned sample size n=~450 Open-label extension to follow TIGER-2 Study Design
Slide 28: Acknowledgements
28 Cystic Fibrosis Foundation CFFT Therapeutics Development Network CFFT Data Monitoring Committee TIGER-1 Principal Investigators and Research Coordinators Acknowledgements
Inspire Pharmaceuticals — Technical Presentation (October 2008) on 6ix